Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process

Universal Ibogaine (TSXV: IBO) remains under a management cease trade order (granted Dec 4, 2025) after missing the Nov 28, 2025 deadline to file audited financials, MD&A and CEO/CFO certifications for the year ended July 31, 2025; the company will issue bi-weekly default reports until filings are completed. UI has temporarily closed its Kelburn Recovery Centre, is negotiating a Letter of Intent for a potential sale of the property, and intends to use part of any sale proceeds to complete the audit and repay recently matured convertible debt with principal owing of $726,500; completion of the audit and filings is contingent on the outcome of the restructuring and any TSXV/regulatory approvals.

Analysis

Market structure: The immediate winners are secured creditors, turnaround buyers and local real‑estate purchasers who can buy the Kelburn property at a discount; equity holders of IBOGF (microcap TSXV/OTC) are the clear losers as an MCTO + potential general CTO materially impairs liquidity and fundraising ability. This increases supply of distressed biotech assets — expect downward price pressure across sub‑$200m market‑cap psychedelic/rehab names for 30–90 days as capital flight occurs, while larger, well‑funded psychedelics (NASDAQ:ATAI, MNMD) retain relative pricing power.

Risk assessment: Tail risks include a general CTO and forced insolvency (high impact, ~10–30% probability absent a sale), Health Canada rejecting any CTA (medium probability, high impact on long term thesis), or TSXV refusing restructuring approval which could kill listing (low‑probability, catastrophic). Near term (days–weeks) the key risks are liquidity squeeze and convertible debt acceleration ($726,500 principal); medium term (30–120 days) hinges on LOI execution and sale proceeds; long term depends on successful CTA and capital markets reopening (6–18 months).

Trade implications: Direct: avoid or short IBOGF via OTC (small size, 0.5–2% NAV short) with tight stop (30% adverse move) and target 50–80% downside on insolvency/CTO. Pair: long larger-cap psychedelics (ATAI 1–2%) vs short IBOGF (0.5–1%) to express sector consolidation. Options: buy deep OTM puts on listed peers only if volatility >60% to hedge sector risk; cash reserve increase (3–5%) recommended for deployment on distressed asset windows.

Contrarian angles: Consensus prices IBOGF as near‑zero; however a completed LOI with proceeds ≥$1.0–1.5M could fund the audit, repay debt and avoid CTO — a rapid 2–4x recovery is possible within 30–60 days if sale closes and filings are made. Historical precedent: microcap biotech asset sales often spike equity ±100% on certainty; therefore consider a tactical asymmetric play (small long conditional on LOI signing) rather than a large directional bet.

Key Decisions for Investors

• Establish a tactical short position in IBOGF sized 0.5–2.0% of portfolio NAV via available OTC shares, set a hard stop-loss at +30% and target a 50–80% decline within 30–90 days contingent on non-closure of a sale or issuance of a general CTO.
• Initiate a pairs trade: long 1.0–2.0% position in ATAI (NASDAQ:ATAI) and simultaneously short 0.5–1.0% IBOGF to capture relative strength in well‑funded psychedelics vs distressed microcap, rebalancing after 60 days or upon LOI announcement.
• Reduce aggregate exposure to microcap psychedelic/rehab equities by 30–50% and reallocate 3–5% of portfolio to cash/short‑duration healthcare names to preserve optionality for distressed asset purchases in the next 30–90 days.
• Set a conditional buy trigger: if UI files an executed LOI and confirms sale proceeds ≥$1.0M and audited financials are filed within 60 days, deploy up to 0.5–1.0% NAV to accumulate IBOGF (recover to neutral) with a take-profit at +100% and stop at -50%.